Synthesis and Comparative Study of Nanoparticles Derived from Bovine and Human Serum Albumins

Tazhbayev, Yerkeblan; Mukashev, Olzhas; Burkeyev, M.Zh.; Lozinsky, V. I.

doi:10.3390/polym12061301

Cited by 9 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that HSA and BSA share 80% sequence homology, their molecular weights differ by less than 1%, and their isoelectric points are identical. Nevertheless, the finding obtained in this study is in agreement with the work conducted by Tazhbayev et al (61), who demonstrated that the average particle size of BSA-derived nanoparticles (167 ± 5 nm) was smaller than that of HSA-derived nanoparticles (216 ± 9 nm).…”

Section: Discussionsupporting

confidence: 93%

Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

et al. 2021

View full text Add to dashboard Cite

Purpose: The ultimate goal of this study is to develop a novel delivery system for a new potent cytotoxic compound, CCI-001, with anti-b tubulin activity, so that the drug can be effectively administered and at the same time its harmful side effects can be reduced. Methods: In the current study, CCI-001 was loaded into serum albumin (SA), using a modified desolvation method, generating CCI-001-SA nanoparticles. Both bovine and human SA were used for the encapsulation of this drug candidate. Optimum conditions for drug loading were achieved when already formed and crosslinked albumin nanoparticles were incubated overnight at 37°C with CCI-001 solutions. The CCI-001-loaded albumin nanoparticles were assessed for average particle diameter and polydispersity, zeta potential, drug loading, in vitro release, morphology and cell toxicity against SW620 and HCT116 colorectal cancer cells. Results: The spherical nanoparticles obtained were negatively charged (~ -30 mV) and had an average diameter of ~ 130 nm, with a narrow size distribution. The in vitro release of CCI-001 from the albumin nanoparticles showed a sustained release pattern over 24 hours without any initial burst release, compared to the fast release of the free drug under experimental conditions. No difference between the SA from the two species in terms of CCI-001 loading was observed. However, a significant difference was observed between the release profiles of CCI-001 from drug-loaded HSA and drug-loaded BSA nanoparticles with HSA nanoparticles showing slower drug release (mean release time, MRT, values of 5.14 ± 0.33 h and 6.88 ± 0.15 h for BSA-NPs and HSA-NPs, respectively, P < 0.01). Cellular toxicity studies showed higher cytotoxicity for CCI-001-SA compared to the free drug (IC50s of 0.62 ± 0.31 nM vs 2.06 ± 0.29 nM in SW620 cells and 0.9 ± 0.1 nM vs 4.2 ± 0.2 nM in HCT116 cells, for CCI-001-HSA NPs and free drug, respectively). Therefore, despite the low drug content level in the HSA nanoparticles of CCI-001, the formulation provides relevant concentrations for further in vivo studies in animal models due to high drug potency. Conclusions: The data support the potential use of albumin as a nanocarrier for CCI-001 in biological systems.

show abstract

Section: Discussionsupporting

confidence: 93%

Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this case, urea plays the role of a chaotropic agent, which unfolds albumin chains and increases the availability for interaction with cysteine. As a result, the thiol-disulfide exchange reaction between BSA NPs macro-chains is stabilized [12][13][14]. In addition, the authors of the present work [15] have shown that cysteine can play a positive role in overcoming MDR.…”

Section: Introductionmentioning

confidence: 60%

“…Albumin-based nanoparticles are mostly produced using glutaraldehyde for macro-chain cross-linking. We were the first to propose a method of obtaining BSA nanoparticles using natural components such as urea and L-cysteine [12,13]. In this case, urea plays the role of a chaotropic agent, which unfolds albumin chains and increases the availability for interaction with cysteine.…”

Section: Introductionmentioning

confidence: 99%

Isoniazid—Loaded Albumin Nanoparticles: Taguchi Optimization Method

et al. 2021

Self Cite

View full text Add to dashboard Cite

Tuberculosis is one of the dangerous infectious diseases, killing over a million people worldwide each year. The search for new dosage forms for the treatment of drug-resistant tuberculosis is an actual task. Biocompatible polymer nanoparticles, in particular bovine serum albumin (BSA), are promising drug carriers. Nanoparticle (NP) parameters such as diameter, polydispersity, bioactive substance loading, and NP yield are very important when it comes to drug transport through the bloodstream. The most well-known and widely used first-line anti-tuberculosis drug, isoniazid (INH), is being used as a drug. BSA-INH NPs were obtained by an ethanol desolvation of an aqueous protein solution in the drug presence. The peculiarity of the method is that natural components, namely urea and cysteine, are used for the stabilization of BSA-INH NPs after desolvation. The characteristics of the obtained BSA-INH NPs are significantly affected by the concentration of protein, isoniazid, urea, and cysteine in the solution. The aim of the present study is to investigate the concentration effect of the system reacting components on the parameters of the NPs that are obtained. We have chosen the concentrations of four reacting components, i.e., BSA, isoniazid, urea, and cysteine, as controlling factors and applied the Taguchi method to analyze which concentration of each component has an important effect on BSA-INH NPs characteristics.

show abstract

“…This interaction had been previously reported in a study involving bovine hemoglobin microparticles [ 26 , 27 ]. In addition, Tazhbayev et al [ 28 ] demonstrated that a urea and cysteine mixture could also be used for cross-linking to affect the conformation change of bovine serum albumin.…”

Section: Resultsmentioning

confidence: 99%

Fabrication and Characterization of Human Serum Albumin Particles Loaded with Non-Sericin Extract Obtained from Silk Cocoon as a Carrier System for Hydrophobic Substances

et al. 2021

View full text Add to dashboard Cite

Non-sericin (NS) extract was produced from the ethanolic extract of Bombyx mori silk cocoons. This extract is composed of both carotenoids and flavonoids. Many of these compounds are composed of substances of poor aqueous solubility. Thus, this study focused on the development of a carrier system created from biocompatible and biodegradable materials to improve the biological activity of NS extracts. Accordingly, NS was incorporated into human serum albumin template particles with MnCO3 (NS-HSA MPs) by loading NS into the preformed HAS-MnCO3 microparticles using the coprecipitation crosslinking dissolution technique (CCD-technique). After crosslinking and template dissolution steps, the NS loaded HSA particles are negatively charged, have a size ranging from 0.8 to 0.9 µm, and are peanut shaped. The degree of encapsulation efficiency ranged from 7% to 57% depending on the initial NS concentration and the steps of adsorption. In addition, NS-HSA MPs were taken up by human lung adenocarcinoma (A549 cell) for 24 h. The promotion of cellular uptake was evaluated by flow cytometry and the results produced 99% fluorescent stained cells. Moreover, the results from CLSM and 3D fluorescence imaging confirmed particle localization in the cells. Interestingly, NS-HSA MPs could not induce inflammation through nitric oxide production from macrophage RAW264.7 cells. This is the first study involving the loading of non-sericin extracts into HSA MPs by CCD technique to enhance the bioavailability and biological effects of NS. Therefore, HSA MPs could be utilized as a carrier system for hydrophobic substances targeting cells with albumin receptors.

show abstract

Synthesis and Comparative Study of Nanoparticles Derived from Bovine and Human Serum Albumins

Cited by 9 publications

References 43 publications

Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

Isoniazid—Loaded Albumin Nanoparticles: Taguchi Optimization Method

Fabrication and Characterization of Human Serum Albumin Particles Loaded with Non-Sericin Extract Obtained from Silk Cocoon as a Carrier System for Hydrophobic Substances

Contact Info

Product

Resources

About